Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CANbridge OK'd to Launch Breast Cancer Drug in Hong Kong

publication date: Nov 5, 2019

CANbridge, a Beijing oncology and rare disease biopharma, announced that Hong Kong approved Nerlynx® (neratinib) as an extended adjuvant treatment for HER2-overexpressed/amplified breast cancer. Patients must have completed adjuvant Herceptin (trastuzumab) therapy within the last year. The company has also filed for approval of the drug in China based on the 2017 FDA acceptance of Nerlynx in the US. CANbridge in-licensed greater China rights to Nerlynx last year from Puma Biotech in a deal that included $70 million in upfront and development milestone payments. More details....

Stock Symbol: (NSDQ: PBYI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.